Nasdaq FDA - Search News

FDA Approves 1st Non-Opioid Pain Drug in 20 Years

FDA approves Vertex's first-in-class non-opioid analgesic for acute pain

Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid analgesic,

Wall Street Journal · 4h

First New Non-Opioid Painkiller in Decades Gets FDA Approval

Vertex Pharmaceuticals won U.S. approval for the first new non-opioid painkiller in decades, which could be a blockbuster if the company can persuade insurers and doctors to embrace the non-addictive alternative to notorious drugs like OxyContin.

Eagle-Tribune · 5h

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.

Axsome, FDA and migraine

Hosted on MSN · 6h

Axsome gets FDA approval for Symbravo for migraine

Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo, a combination of meloxicam and rizatriptan,

Reuters on MSN · 4h

US FDA approves Axsome Therapeutics' migraine drug

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday. The oral drug, branded Symbravo, was approved for the acute treatment of the condition characterized by recurrent attacks of moderate to severe throbbing and pulsating pain on one side of the head.

Business Insider · 7h

Axsome Therapeutics announces FDA approval of Symbravo

Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in

Nasdaq3d

Invivyd Submits Updated Immunobridging Data To FDA For PEMGARDA EUA Amendment

Invivyd has continued to provide timely updates to the FDA since its initial submission ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

6hon MSN

Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

Biotech Stocks Facing FDA Decision In February 2025

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Nasdaq3d

Alvotech: FDA To Review BLA For AVT05 - Quick Facts

The FDA review process is anticipated to be completed ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

3don MSN

Atara to cut 50% of workforce amid FDA woes

Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo. The ...

Axsome Shares Up Post Market After Hitting Record High on FDA Approval

Symbravo, for the acute treatment of migraine with or without aura in adult patients, showed superior efficacy across a broad range of severity, Axsome said Thursday. A single oral dose gave patients ...

Nasdaq3d

Cartesian Therapeutics Secures FDA SPA Agreement For Phase 3 AURORA Trial

Descartes-08 has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation from the FDA for MG and other ... reflect those of Nasdaq, Inc. Founded in the late 1990s ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results